Calibrate的动态

Obesity, affecting over 1 billion people globally, presents a complex health challenge intensified by genetic and environmental factors. Equitable access remains elusive despite advancements in treatments, including medications and surgeries. The landscape is evolving rapidly with the rise of startups aiming to democratize obesity care through digital health innovations and advanced pharmacotherapies (see image below). The treatment spectrum spans lifestyle interventions, antiobesity medications like GLP-1 agonists, and bariatric procedures, each with varying degrees of effectiveness and patient suitability. The burgeoning obesity market, driven by a blend of direct-to-consumer (Ro,?Noom,?Calibrate) and business-to-business (Transcarent,?twenty30 health,?Found) models, underscores the need for a multimodal, patient-centered approach in combating obesity. I feel the healthcare sector will soon witness a pivotal shift from D2C models towards B2B models, aiming to fully integrate obesity management into patient care plans. This evolution promises not just improved accessibility but a holistic, patient-centric approach to obesity care. As we stand at the crossroads of clinical practice and digital health innovation, the future of obesity care hinges on integrating medical breakthroughs with scalable, accessible solutions. The goal? To ensure comprehensive, equitable care for all affected by obesity. My full exploration of the obesity space, including its mechanisms, treatments, and evolving market landscape, is exclusive to Healthcare Huddle's premium subscribers. Click the link to read my entire analysis: [https://lnkd.in/epxv5Va5] #obesity #GLP1 #pharma #globalhealth #publichealth #healthtech #digitalhealth

The ?????????????? ???????? ?????????????????? ???? ???????????????????????? ?? ???????????????????????????? like never before, driven by the launch of GLP-1 therapies. At Rock Health Advisory, we‘ve identified?a serviceable addressable market of digital health obesity treatments at an impressive $7B. Through our work, we’ve uncovered ?????????????????????? ?????? ???? ???????????????? ???????????? ???????????????????? ?????? ?????????????????? ?????????????? ????????: ?? ?????? ???????? ???????????????? ????????????: With an estimated 1.3M patients treated with GLP-1s for weight loss (excludes T2D), partnerships, like those of Lilly, Mayo Clinic, and Transcarent, are playing a key role in enabling access to comprehensive, patient-centered care? ?????????????????????? ????????: The integration of care navigation, behavior change solutions, and/or connected devices/sensors is proving essential to enhancing patient well-being and adherence to treatments and controlling costs for employer/payers ??? ?????????????????? ??????????????????: Tailored nutritional support is a cornerstone of sustainable health, especially in conjunction with medication-assisted therapies, highlighting the role of “food as medicine” in ongoing weight management and maintenance ???????????????????? ?????????????????? ????????????????: Customized care pathways, grounded in biomarker testing and phenotype / risk stratification, are likely to define the future of obesity treatment, promising more effective and personalized weight management strategies At Rock Health Advisory, we’ve been supporting our clients in pursuing innovation opportunities for obesity care—to get support on your strategy, reach out via DM. #HealthcareInnovation #DigitalHealth #Obesity #ObesityCare #GLP1s #WeightManagement

Yesterday, I attended Digital Health New York's Obesity + Health conference with Victoria D.. The conference was a half day of goodness, but there were two sessions that stood out to me. The first was a panel discussion titled Patient Point of View: It’s About More Than Weight Loss where 3 people with obesity discussed their experiences ranging from medications to bariatric surgery to a supervised ketogenic diet supported by an app (Virta Health), care team, and community. Listening to people's struggles and hope reminded me why I decided to devote a significant part of my career to obesity. It also illustrated well how different people have different preferences, values, and responses to different interventions. One panelist used only a nutritional intervention with exercise, another was using a GLP-1 medication, and the third had undergone bariatric surgery years earlier and was also using multiple drugs to maintain her weight. The second was when panelist Katherine Saunders, MD spoke about her perspectives on obesity medication that closely mirror my own. Why are we so focused on maximizing doses of monotherapy with medications that have many side effects that are more common and prominent at higher doses? It is common knowledge that many medications produce much of their benefits at lower dosages, while side effects are dose dependent. Thus, previous research has shown better tolerability with good efficacy for multiple drugs at lower doses for other conditions like high blood pressure and lipid disorders. It's high time we start thinking about multi-drug regimens earlier rather than always maximizing doses of monotherapy AOMs. Hats off to Bunny Ellerin for a great conference! #obesity #pharmacotherapy #antiobesitydrugs #obesitymedicine #keto #glp1s

??? As the public conversation around #obesitycare evolves, we're increasingly moving #beyondBMI to more #comprehensive #tools for assessing #bodycomposition. ?? I’m particularly passionate about how #bioimpedanceanalysis fits into the clinical space, offering high-quality insights into a patient’s fat, muscle, and fluid balance, which enables more personalized and accurate treatment approaches. ?? This recent The New York Times article by Julia Belluz "Are We Thinking About Obesity All Wrong?" highlighted the ongoing debate about #obesity as a #disease, focusing on how #BMI, while widely used, falls short in diagnosing the condition accurately. BMI doesn’t capture fat distribution or its impact on organ function, which is where #bioimpedance plays a critical role. As obesity treatments like GLP-1 receptor agonists and other #NuSH #incretins #obesitymedications rise in popularity, the need for more #precise #diagnostic #tools is urgent. These tools must differentiate those who are truly #atrisk from those with #excessweight but no associated health risks. ??This quote resonates: "Obesity, as it’s currently understood, doesn’t reflect what we now know about body fat. It makes patients out of people who aren’t ill and glosses over those who need health care urgently. In declaring a disease without nailing down what the disease is, the medical community left obesity open to debate among doctors, insurers and everyday people. This in turn left people with obesity vulnerable, their bodies subject to accusations and questioning, overtreatment, undertreatment and mistreatment." ?? I’m excited about the potential for more #sophisticated metrics like #bioimpedance to help us move #beyond the #limitations of BMI and offer a more #nuanced view of health. With this approach, we can better identify those with obesity-related health risks and refine the definition of "clinical obesity" based on organ and tissue dysfunction, not just body size. ?? to article: https://lnkd.in/eJ9J_R-b

While this article is about using Real World Evidence to derive insights about obesity, I am a big believer that RWE utilisation is only going to increase as our ability to capture and process large volumes of data becomes more and more common. Personally, with my interest in pain management, I would love to see something similar for chronic pain, which along with obesity, has such a massive burden of disease that the value to be gained from understanding this widespread condition would be well worth the costs of anaylsis. #obesity #healthcare #realworldevidence #RWE #realworlddata IQVIA Institute for Human Data Science https://lnkd.in/gvTA89GV

?? What a great read - a qualitative study to understand the #risks of #obesity #treatment from the #perspective of people living with obesity! ?? Risks were described under 3 categories: 1?? Treatment #Access ?? Lack of reimbursement, limited or no insurance coverage, long waiting lists, narrowly defined eligibility criteria, exclusions, losing access when BMI improves 2?? Treatment #Expectations ?? Unmet expectations from self, healthcare providers, family, friends, society, advertising, seeing treatment as a fix, weight regain/recurrence, self-blame, feeling disheartened or disappointed by slow progress, social judgement, stigma, misconceptions about obesity as a lifestyle choice or "the easy way out" 3?? Treatment #Success ?? Fear of personal transformation, developing new coping mechanisms when food no longer provides emotional relief, weight loss leading to being treated differently, being perceived as "more acceptable", social dynamic changes, feelings of loneliness, discomfort with new realities, importance of taking action compared to risks of inaction ?? For me this highlights the importance of the patient voice in understanding and improving obesity treatment access and outcomes! They highlight that understanding the patient lived experience drives improvements in treatment design, quality and outcomes. It offers clinicians and research scientists a rich understanding of the positive and negative aspects of the patient journey and enables them to address concerns that patients might have about obesity treatment. Great work Joe Nadglowski, Dr Deirdre McGillicuddy, Eva Hollmann ??

Paper #3 Despite a range of new options, the percentage of people with obesity accessing treatment remains disproportionately low. Efforts to understand this disparity have focused on treatment barriers and the perspectives of healthcare professionals. We decided to ask people living with obesity. https://lnkd.in/du_2xGnW People living with obesity described three mains risks to obesity treatment: 1) Access: "A risk of treatment is simply that you don’t get it" – Lydia 2) Expectations: “people do feel that if you’ve had treatment for obesity, how could you gain weight again?” - Anna 3) the risk that the treatment would be ‘successful’ but that they would lose their sense of self, their coping mechanisms and identity along with weight. These papers have three findings in common: 1) Obesity is more than weight on a scale. It is a complex disease requiring ongoing support using multidisciplinary approaches, 2) The stigma, shame, blame and discrimination faced by PwO significantly compounds the effects of the disease. 3) Effective responses to the treatment of obesity must involve the voices and perspectives of people living with the disease. Which I've written about before (and will likely do so again!) Finally I would like to thank all those who so generously shared their experiences of living with obesity. I hope that by showing how much we can learn about obesity by simply asking people who live it, we have advanced the scientific understanding in meaningful ways.

A faulty definition on "obesity" is making patients out of people who are not sick. It is high time that a group of experts got together again to discuss what even is the definition of obesity and if it is going to be called a disease. Continuing to use BMI as a diagnostic tool for "one of the most polarizing medical conditions" is just not going to cut it. Having a group of experts revise the definition of obesity today is a topic that demands attention, escpecially in light of the new weight loss medications. I found this article really helpful at pinpointing what are some of the most pressing issues for the debate on obesity and its definition. https://lnkd.in/edKFdykQ

Today, I want to address an important issue that I think is often framed incorrectly regarding obesity treatment. Yesterday, Elli Lilly released topline results of the SUMMIT study evaluating the treatment of HFpEF with tirzepatide. I hope to post some details about the study once it is published, but as expected the results favored tirzepatide over placebo for: ? Heart failure outcomes ? Heart failure symptoms ? Weight loss ? Exercise capacity ? Inflammation We know that not all obesity is the same. Some people will develop severe disease, such as diabetes, sleep apnea, coronary artery disease, heart failure, etc. at a given level of adiposity (body fat), while others may have none of these and be apparently healthy at the same anthropometric measurements. Many people argue we should therefore reserve more intensive treatments, such as GLP-1 agonists and bariatric surgery, only for those with the highest disease burden. This is especially true considering the high cost and limited availability of these high-intensity treatments. I understand this approach, but I disagree with it. We need to start by separating what makes sense medically from resource and cost considerations. There is a time to discuss them together, but we can only do that after we determine what makes sense medically. Obesity is a risk factor for other severe diseases, and we should treat it just like we do other risk factors. Let's take the example of hypertension. Hypertension is a risk factor for stroke, heart attack, heart failure, and chronic kidney disease. However, not everyone with hypertension will go on to develop one of these severe outcomes. Does anyone argue that we should wait until after someone has a stroke or develops heart failure to treat their blood pressure to goal?? I believe when we go through such a thought experiment seriously, we will come to the conclusion that this idea applied to obesity reveals bias. Cost and access considerations are important, but we cannot let them dictate what we believe to be the correct medical approach. There is another side to this argument, which I plan to write about on Monday. In the meantime, I'd love to hear what you think. Please share your thoughts in the comments. #stigma #bias #weightbias #obesity #treatingobesity #tirzepatide #zepbound #prevention

Most of the 50% of Americans struggling with overweight or #obesity will start their weight loss journey with their primary care physician. The challenge to stay on top of advances in obesity management and treatment can be overwhelming. Management and Treatment of Obesity in Primary Care: An Evolving Landscape is a new CME program exploring the latest evidence on lifestyle, pharmacological, and surgical interventions, as well as recent progress in understanding the causes of obesity. Consisting of four distinct learning opportunities, each activity aims to equip primary care clinicians to navigate the complex, evolving landscape of obesity management. In this course you will learn and reinforce your understanding and skills of how to: ?? Examine the roles of environmental and genetic factors in obesity. ?? Articulate the mechanisms and pathophysiology of obesity. ?? Review common risk factors and comorbidities associated with obesity. ?? Assess multiple factors that influence the prevalence of obesity among diverse populations. ?? Evaluate the evolving landscape of nutrient-stimulated hormone-based treatment options for obesity, and management of common side effects of these medications for your clinical practice. ?? Apply knowledge of current best practices in obesity management to confidently manage patients with obesity. Confidently manage patients with obesity. Learn more about this free CME program: https://nej.md/4crgXwz